CTTH - CTT Pharma Announces CEO and New Corporate Strategy
(TheNewswire)
Tampa, Florida, United States – TheNewswire- March 14, 2022 - CTTPharmaceutical Holdings, Inc. ( OTC: CTTH) ispleased to announce the appointment of Ryan Khouri as its new CEO. MrKhouri has years of experience bringing complicated transactions totheir successful conclusion. In addition, he has trained numeroussales professionals on how to develop strategies that best optimizesales returns and drive bottom-line improvements.
Mr Khouri's engagement with the Companystarted as an investor who viewed CTT's unique drug delivery system asthe future industry standard. Mr Khouri stated, "CTT'sdissolvable strips are the next evolution in delivery, taking us awayfrom the inefficiencies of pills and gummies. Our patented strips makeTHC, CBD, Psychedelics, Nicotine and other medicinal actives moreconvenient and precise by directly entering the bloodstreamsublingually, bypassing the lungs and digestive tract, including theliver. Our strips are dosage controlled, have a rapid onset, a highabsorption rate, offer zero calorie/sugar, and match various requestedflavour profiles. In combination with our diverse patent catalogue,the technology's versatility allows us to approach customers fromdifferent industries, offering innovative products across multipleproduct lines. We have the IP we need to execute oncommercialization."
Dr Modi has stepped down as Presidentand as a board member to assist sales teams with technical know-howand formulation. Dr Modi states, "we have developed an extensiveportfolio of IP around our drug delivery technology which includes six (6) US and Canadianpatents as well as worldwide PCT patents that cover an additionalfifty-two (52) countries. These patents cover formulations, processes,and technologies for fast dissolving, high bio-available strips with arapid onset of action. These patents are suitable for anypharmaceutical products, including Nicotine, Cannabinoids,Psychedelics, and a host of other API compounds. Now is the time tofocus on commercializing our patents through partnerships and sales,as these will be the key factors that enhance shareholdervalue".
CTT Pharmaceuticals will be asales-centered company that will focus on commercializing our IP andremoving barriers to sales, such as large milestone payments thatlimit the size and scale of potential partners. CTT will keep itsshareholders updated as it executes on new partnerships and furtherevolves its patent portfolio.
CTT is a drug delivery technologycompany. It has successfully received Health Canada approval, afterwhich it brought its first product to market as cannabinoid-infused'Dissolve Strips'. This successful launch sold out in several weeks toonly 85,000 medical patients online with no advertising.
CTT's common shares trade on the OTCmarket in the United States under the symbol"CTTH".
Ryan Khouri - 813-606-0060 - Rkhouri@cttpharmaceuticals.com
www.cttpharmaceuticals.com
Copyright (c) 2022 TheNewswire - All rights reserved.